Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.

The MRC/NCRI cohort included 9% patients with high-risk MDS, while the SWOG trials only enrolled AML patients. While, overall, AML has remained difficult to cure, the likelihood of resistance to treatment and/or treatment-related mortality varies greatly across individual patients. To the Editor Regulatory approval of several new drugs has expanded the therapeutic options for adults with acute myeloid leukemia (AML) [[1], [3]]. [Extracted from the article]